- Home
- NTRA vs CRBG Comparison
NTRA vs CRBG Comparison
Compare NTRA & CRBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- CRBG
- Stock Information
- Founded
- NTRA 2003
- CRBG 1957
- Country
- NTRA United States
- CRBG United States
- Employees
- NTRA N/A
- CRBG N/A
- Industry
- NTRA Medical Specialities
- CRBG Life Insurance
- Sector
- NTRA Health Care
- CRBG Finance
- Exchange
- NTRA Nasdaq
- CRBG Nasdaq
- Market Cap
- NTRA 18.4B
- CRBG 18.9B
- IPO Year
- NTRA 2015
- CRBG 2022
- Fundamental
- Price
- NTRA $143.94
- CRBG $31.35
- Analyst Decision
- NTRA Strong Buy
- CRBG Strong Buy
- Analyst Count
- NTRA 17
- CRBG 14
- Target Price
- NTRA $179.00
- CRBG $37.29
- AVG Volume (30 Days)
- NTRA 1.9M
- CRBG 2.8M
- Earning Date
- NTRA 05-08-2025
- CRBG 05-02-2025
- Dividend Yield
- NTRA N/A
- CRBG 3.04%
- EPS Growth
- NTRA N/A
- CRBG 117.54
- EPS
- NTRA N/A
- CRBG 3.72
- Revenue
- NTRA $1,696,911,000.00
- CRBG $18,640,000,000.00
- Revenue This Year
- NTRA $13.56
- CRBG $20.17
- Revenue Next Year
- NTRA $18.11
- CRBG $5.58
- P/E Ratio
- NTRA N/A
- CRBG $8.66
- Revenue Growth
- NTRA 56.75
- CRBG N/A
- 52 Week Low
- NTRA $83.13
- CRBG $23.97
- 52 Week High
- NTRA $183.00
- CRBG $35.36
- Technical
- Relative Strength Index (RSI)
- NTRA 41.35
- CRBG 43.38
- Support Level
- NTRA $146.35
- CRBG $31.93
- Resistance Level
- NTRA $155.64
- CRBG $33.05
- Average True Range (ATR)
- NTRA 6.42
- CRBG 1.00
- MACD
- NTRA 0.87
- CRBG -0.01
- Stochastic Oscillator
- NTRA 51.93
- CRBG 25.59
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments namely Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.